Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages 1806-1812

  Gabay, Cem ^a   Mcinnes, Iain B ^b   Kavanaugh, Arthur ^c   Tuckwell, Katie ^d   Klearman, Micki ^e   Pulley, Jennifer ^d   Sattar, Naveed ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e GENENTECH INC   (United States)

Author keywords

Cardiovascular Disease; Inflammation; Lipids; Rheumatoid Arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN A; MONOCLONAL ANTIBODY; SECRETORY PHOSPHOLIPASE A2; SERUM AMYLOID A; TOCILIZUMAB;

ADULT; ARTHRITIS, RHEUMATOID; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PHOSPHOLIPASES A2, SECRETORY; RISK FACTORS; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME;

EID: 85021858218     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207872     Document Type: Article

References (39)

1. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65: 1608-12.
2. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59: 1690-7.
3. del Rincón I, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44: 2737-45.
4. Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108: 2957-63.
5. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70: 482-7.
6. Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999;100: 1280-4.
7. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836-43.
8. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007;27: 1177-83.
9. Robertson J, Peters MJ, McInnes IB, et al. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013;9: 513-23.
10. Lee YH, Choi SJ, Ji JD, et al. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000;19: 324-5.
11. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361: 2518-28.
12. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012;32: 1732-41.
13. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301: 2331-9.
14. Boffa MB, Koschinsky ML. Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep 2013;15: 360.
15. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68: 460-9.
16. McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2015;74: 694-702.
17. Daïen CI, Duny Y, Barnetche T, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012;71: 862-8.
18. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64: 303-5.
19. Wijbrandts CA, van Leuven SI, Boom HD, et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68: 1316-21.
20. Cauza E, Cauza K, Hanusch-Enserer U, et al. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002;114: 1004-7.
21. Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069: 414-19.
22. Hjeltnes G, Hollan I, Førre O, et al. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-alpha-inhibitor. Clin Exp Rheumatol 2013;31: 415-21.
23. Sattar N, Crompton P, Cherry L, et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56: 831-9.
24. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381: 1541-50.
25. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13: R141.
26. Chiba H, Akizawa K, Fujisawa S, et al. A rapid and simple quantification of human apolipoprotein E-rich high-density lipoproteins in serum. Biochem Med Metabolic Biol 1992;47: 31-7.
27. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31: 2844-53.
28. Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015;67: 616-25.
29. Jahangiri A, de Beer MC, Noffsinger V, et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009;29: 261-7.
30. Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004;15: 269-78.
31. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45: 1169-96.
32. Chait A, Han CY, Oram JF, et al. Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46: 389-403.
33. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340: 448-54.
34. Müller N, Schulte DM, Türk K, et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res 2015;56: 1034-42.
35. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012;71: 687-93.
36. Jamnitski A, Levels JH, Van Den Oever IA, et al. High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol 2013;40: 825-30.
37. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011;50: 518-31.
38. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63: 522-9.
39. Rao VU, Pavlov A, Klearman M, et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 2015;67: 372-80.